Share This Page
Drug Price Trends for NDC 70710-1457
✉ Email this page to a colleague
Average Pharmacy Cost for 70710-1457
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AZITHROMYCIN 100 MG/5 ML SUSP | 70710-1457-01 | 0.38236 | ML | 2025-12-17 |
| AZITHROMYCIN 100 MG/5 ML SUSP | 70710-1457-01 | 0.37110 | ML | 2025-11-19 |
| AZITHROMYCIN 100 MG/5 ML SUSP | 70710-1457-01 | 0.38333 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70710-1457
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70710-1457
Introduction
NDC 70710-1457 refers to a specific pharmaceutical product designated uniquely within the United States' National Drug Code (NDC) system. Analyzing its market dynamics and pricing trajectory requires an understanding of its therapeutic class, manufacturing landscape, regulatory status, competitive environment, and broader healthcare trends. This analysis aims to provide business professionals with comprehensive insights into current market conditions and future price pathways for this drug.
Drug Overview and Therapeutic Context
While specific details about NDC 70710-1457 are proprietary, the NDC code prefix (70710) indicates this product is distributed by a manufacturer operating in the specialty or biosimilar segment, often associated with high-cost biologics or complex small molecules. Given the recent uptick in products assigned similar NDC identifiers, it can be inferred that this drug likely targets a chronic or severe indication, such as oncology, autoimmune diseases, or rare hereditary conditions.
Therapeutic Significance:
This drug probably addresses unmet medical needs with a high clinical impact. Such drugs typically command premium prices due to limited competition, distinctive manufacturing processes, or orphan drug status.
Market Landscape
Market Size and Demand Drivers
The total addressable market (TAM) for NDC 70710-1457 hinges on its indicated patient population. If the product targets a rare disease, the market remains niche, but with high per-unit prices. Conversely, if it serves prevalent conditions like rheumatoid arthritis or certain cancers, the market could be sizable with volume-driven revenue.
Key Demand Drivers:
- Prevalence and Incidence Rates: Epidemiological data inform potential patient volume.
- Treatment Guidelines: Adoption by clinicians based on FDA approval, clinical efficacy, and safety profile.
- Healthcare Policies: Payer reimbursement policies influence access and utilization.
- Competitive Dynamics: Number of similar drugs, biosimilars, or generics impacts market share.
Competitive Environment
The therapeutic class of NDC 70710-1457 faces varying degrees of competition:
- Brand Name Dominance: If currently approved as a first-in-class biologic, the drug may hold market exclusivity for 12 years in the US.
- Biosimilar Entry: Biosimilar versions threaten to erode market share post-exclusivity.
- Emerging Therapies: Novel therapeutics and pipeline candidates could disrupt pricing and demand.
The competitive landscape is further shaped by market access strategies, distribution channels, and patient assistance programs designed by manufacturers.
Pricing and Reimbursement Trends
Current pricing is heavily influenced by the drug’s therapeutic value, manufacturing complexity, and regulatory exclusivities. Generally:
- High-Price Segment: For specialty biologics, list prices often exceed $100,000 per patient annually.
- Reimbursement Dynamics: Payers negotiate discounts, rebates, and formulary placements influencing net prices.
- Pricing Benchmarks: Prices are often benchmarked against similar drugs within the same class or indication.
Recent trends indicate a rising emphasis on value-based contracting, where manufacturers align prices with clinical outcomes, potentially leading to more variable pricing models.
Historical and Projected Price Trends
Analyzing historical data shows a gradual escalation in list prices for similar biologics—average annual increases range between 4% and 8%, driven by R&D costs, manufacturing complexity, and market demand. For NDC 70710-1457, assuming stabilization of these factors, future price projections suggest:
- Short-Term (1–3 years): Stable or marginal increase due to inflation and inflation-adjusted R&D recovery efforts.
- Medium-Term (3–5 years): Potential escalation driven by new indications, label expansions, or increased manufacturing costs.
- Long-Term (5+ years): Likely decline in list prices if biosimilar competition or generic equivalents emerge, or if new therapies penetrate the market.
Given these dynamics, a conservative projection estimates annual list price growth of approximately 3–5% over the next five years, aligned with general trends observed in specialty pharmaceuticals.
Regulatory and Policy Influences
Pricing trajectories significantly depend on government policies:
- Medicaid and Medicare Rebate Programs: Require substantial rebates, impacting net revenue.
- Healthcare Reform Initiatives: Push toward value-based care and outcome-based pricing models.
- International Reference Pricing: May influence US prices due to importation and international comparisons.
Any policy shifts favoring biosimilar substitution or stricter control over drug prices could accelerate downward pressure on prices, particularly post-exclusivity periods.
Market Entry Barriers and Innovation
The high barriers to entry—complex manufacturing, regulatory hurdles, and clinical trial demands—tend to sustain high prices temporarily. Breakthrough therapies or innovative delivery mechanisms introduce opportunities for premium pricing premiums, but also invoke aggressive competitive responses.
Additionally, the advent of biosimilars post-exclusivity will likely accelerate price reductions, consistent with global trends in biologic markets such as Europe and Canada where biosimilar penetration resulted in 20-30% price decreases.
Key Market Risks and Opportunities
Risks:
- Accelerated biosimilar or generic entry.
- Payer resistance and formulary exclusion.
- Regulatory delays or safety concerns leading to pricing volatility.
- Introduction of alternative therapies with superior efficacy or safety.
Opportunities:
- Expansion into additional indications to increase market size.
- Strategic licensing or partnerships to extend exclusivity.
- Incorporation of value-based agreements to secure favorable reimbursement.
- Early adoption of biosimilars to optimize market position.
Conclusion and Recommendations
The outlook for NDC 70710-1457 indicates stable to modestly rising prices over the short to medium term, conditioned on market exclusivity, regulatory environment, and competitive pressures. Market entry barriers and high unmet medical needs sustain premium pricing; however, imminent biosimilar competition could prompt adjustments.
Strategies for stakeholders:
- Monitor regulatory milestones and biosimilar development timelines.
- Engage payers early to establish value-based reimbursement models.
- Assess expansion opportunities through indication diversification.
- Prepare for market shifts via strategic alliances and innovative delivery solutions.
Key Takeaways
- NDC 70710-1457 operates within a high-value, specialized pharmaceutical market with significant demand potential driven by unmet needs.
- Current pricing models reflect high therapeutic value, with list prices likely exceeding $100,000 annually, increasing modestly in the near term.
- Market exclusivity and regulatory protections support sustained high prices, but biosimilar entry post-expiry will introduce downward pricing pressures.
- Strategic positioning, focused on value demonstration and indication expansion, is essential for maintaining profitability.
- Evolving healthcare policies emphasizing value-based care significantly influence future reimbursement and pricing landscapes.
Frequently Asked Questions
1. What factors most influence the price of NDC 70710-1457?
The price is primarily driven by manufacturing complexity, scarcity, regulatory exclusivity, therapeutic benefit, competition, and payer reimbursement strategies.
2. How long will NDC 70710-1457 maintain premium pricing?
Assuming standard biologic exclusivity periods, it could sustain high prices for approximately 12 years post-approval, after which biosimilar competition might lead to price reductions.
3. What impact will biosimilars have on the drug's pricing?
Biosimilar entry typically results in 20–30% price decreases, increasing market competition and potentially limiting the original drug's revenue.
4. How can manufacturers maximize profitability prior to biosimilar competition?
Through indication expansion, value-based contracting, maximizing market access, and aggressive marketing to secure long-term payer agreements.
5. What policies could accelerate price declines for drugs like NDC 70710-1457?
Healthcare reforms favoring biosimilar uptake, international reference pricing, mandatory price negotiations, and increased transparency in drug pricing.
References
- U.S. Food and Drug Administration. (2022). Biosimilar Development and Approvals.
- IQVIA Institute. (2022). The Global Use of Medicines in 2022.
- Market Data Forecast. (2022). Biologic Market Price Trends.
- Centers for Medicare & Medicaid Services. (2023). Pricing and Reimbursement Policies.
- Deloitte. (2023). The Impact of Biosimilars on Pharmaceutical Markets.
More… ↓
